HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target

Benzinga · 10/17 10:55
HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $22 price target.